Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Raw Materials (2016 - 2020)

United Therapeutics' Raw Materials history spans 11 years, with the latest figure at $20.1 million for Q1 2020.

  • For Q1 2020, Raw Materials fell 9.87% year-over-year to $20.1 million; the TTM value through Mar 2020 reached $20.1 million, down 9.87%, while the annual FY2019 figure was $21.1 million, 13.17% down from the prior year.
  • Raw Materials for Q1 2020 was $20.1 million at United Therapeutics, down from $21.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $29.1 million in Q2 2017 and bottomed at $19.3 million in Q3 2019.
  • The 5-year median for Raw Materials is $24.8 million (2016), against an average of $24.4 million.
  • The largest annual shift saw Raw Materials grew 17.34% in 2017 before it fell 25.77% in 2019.
  • A 5-year view of Raw Materials shows it stood at $25.4 million in 2016, then rose by 9.84% to $27.9 million in 2017, then dropped by 12.9% to $24.3 million in 2018, then dropped by 13.17% to $21.1 million in 2019, then decreased by 4.74% to $20.1 million in 2020.
  • Per Business Quant, the three most recent readings for UTHR's Raw Materials are $20.1 million (Q1 2020), $21.1 million (Q4 2019), and $19.3 million (Q3 2019).